References
- ChristiansenCSkeletal osteoporosisJ Bone Miner Res19938Suppl 2S475S4808122515
- OrimoHNakamuraTHosoiTIkiMJapanese 2011 guidelines for prevention and treatment of osteoporosis–executive summaryArch Osteoporos2012732023203733
- HalleenJHentunenTAHellmannJVäänänenHKTartrate-resistant acid phosphatase from human bone: purification and development of an immunoassayJ Bone Min Res1996111014441452
- HalleenJMAlataloSLSuominenHChengSJanckilaAJVäänänenHKTartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorptionJ Bone Miner Res20001571337134510893682
- NishizawaYOhtaHMiuraMGuidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)J Bone Miner Metab201331111523143508
- NakamuraTMatsumotoTSugimotoTClinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)J Clin Endocrinol Metab20149972599260724646104
- NakamuraYSuzukiTKamimuraMIkegamiSUchiyamaSKatoHVitamin D and calcium are required at the time of denosumab administration during osteoporosis treatmentBone Res201751605528690911
- CummingsSRSan MartinJMcClungMRFREEDOM TrialDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
- MillerPDPannacciulliNBrownJPDenosumab or Zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonatesJ Clin Endocrinol Metab201610183163317027270237
- RecknorCCzerwinskiEBoneHGDenosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialObstet Gynecol201312161291129923812464
- RouxCHofbauerLCHoPRDenosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label studyBone201458485424141036
- KamimuraMNakamuraYIkegamiSUchiyamaSKatoHTaguchiASignificant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patientsOsteoporos Int201728255956627650642
- NakamuraYSuzukiTKamimuraMIkegamiSUchiyamaSKatoHAlfacalcidol increases the therapeutic efficacy of ibandronate on bone mineral density in Japanese women with primary osteoporosisTohoku J Exp Med2017241431932628458336
- NakamuraYSuzukiTYoshidaTYamazakiHKatoHVitamin D and calcium are required during denosumab treatment in osteoporosis with rheumatoid arthritisNutrients201795 pii: E428
- NakamuraYKamimuraMIkegamiSChanges in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term studyBMC Endocr Disord2015158126666998
- CatalanoAGaudioAMorabitoNQuantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumabJ Endocrinol Invest201740885185728332172
- BauerDCBlackDMGarneroPFracture Intervention Trial Study GroupChange in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trialJ Bone Miner Res2004191250125815231011
- EbinaKKashiiMHiraoMComparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosisJ Bone Miner Metab Epub2016119
- SuzukiTNakamuraYKamimuraMIkegamiSUchiyamaSKatoHCompliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosisOsteoporos Sarcopenia201732108111